Investors

To download our documents

Events

All events
27/03/2025

Smallcap Event, Paris

March 27th, 2025, Paris

Read more
05/03/2025

Lusvertikimab & the Future of IBD: KOL Insights Post-ECCO

Save the date and join OSE Immunotherapeutics on 5 March at 6pm CET | 12pm ET for an exclusive webinar featuring top key opinion leaders (KOLs) and industry experts on…

Read more
19/02/2025

20th Congress of European Crohn’s and Colitis Organization (ECCO)

Februay 19-22, 2025 - Berlin, Germany

Read more

Live stock price

OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris

Share price

ISIN

FR0012127173

Ticker

OSE

Type of listing

Continuous

Number of outstanding shares

21,827,777 shares as of June 30, 2024

Eligibility

Eligible to Long-Only Deferred Settlement Service

Financial calendar

This calendar is indicative and may be amended. Financial results are published after market close (Euronext Growth Paris).

26 March 2025

Annual financial results 2024

25 June 2025

General shareholders' meeting

25 September 2025

Half-year results 2025

Analysts

Read more
Edison
Arron Aatkar
Invest Securities
Jamila El Bougrini
Kepler Cheuvreux
Pierre-Alexandre Desir

Analyst reports

Read more
03/04/2025 Edison: Primed for value appreciation
27/03/2025 All invest Securities: RÉSULTAT NET POSITIF GRÂCE À UNE ANNÉE 2024 RICHE EN BD
07/03/2025 Edison: KOL event highlights lusvertikimab's potential

Regulated information

Read more

Professional Equality Index

Read more
25/02/2025 Index égalité professionnelle 2025
27/02/2024 Index égalité professionnelle 2024

General shareholders' meetings

Read more
19/06/2024

General Shareholders' Meeting 2024

All the documents below are in French except the Voting form and the Presentation of nominees for the position of director

Results of the votes

Financial information and publications

Read more
2024 First-half 2024 semester report (in French)
2024 2023 Universal registration document
2023 First-half 2023 financial report (in French)

To receive OSE Immunotherapeutics’ latest news